Internal Medicine Update

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight.

The new oral tablet is also indicated for reducing the risk of major adverse cardiovascular (CV) events in adults with established CV disease who have obesity or overweight.

This approval offers another option for patients who may prefer oral administration. For complete prescribing information & safety data:http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf

Metformin was associated with a lower rate of asthma attacks, with further reductions with the use of GLP-1RA. https://ja.ma/40OTLVZ